Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
STTK
SELLShattuck Labs, Inc. · Healthcare · United States · $710M · Avg Vol: $12M/d
COMPANY DESCRIPTION
Shattuck Labs is a clinical-stage biotechnology company focused on developing novel immune-oncology and autoimmune disease therapies using its proprietary ADAPTIR™ platform. This platform engineers bifunctional fusion proteins designed to simultaneously deliver co-stimulatory and co-inhibitory signals, offering a differentiated approach to modulate the immune system. As a niche player, Shattuck aims to disrupt established treatment paradigms in areas of high unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.7M | 1.7M | 5.7M | 1.0M | 15.3% | 1.0M | — | — | — |
| EPS | -1.07 | -1.01 | -0.74 | -0.70 | — | -0.51 | -0.48 | -0.50 | — |
| Shares | 95.5M | 95.5M | 95.5M | 63.3M | -33.7% | — | — | — | — |
| Debt | 4.9M | 4.2M | 3.4M | 2.4M | -21.0% | 2.9M | — | — | — |
| Equity | 176.2M | 144.7M | 79.6M | 82.4M | -22.4% | — | — | — | — |
| Op CF | -94.5M | -81.2M | -60.5M | -39.9M | — | -41.3M | — | — | — |
| Inv CF | 49.4M | 110.9M | -8.5M | -7.9M | — | — | — | — | — |
| Fin CF | 0.2M | 48.6M | 0.8M | 44.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STTK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STTK | Shattuck Labs, Inc.(you) | $710M | 26 | SELL |
| DSGN | Design Therapeutics, Inc. | $736M | 26 | SELL |
| DRUG.CN | Bright Minds Biosciences Inc. | $727M | 24 | SELL |
| AURA | Aura Biosciences, Inc. | $729M | 24 | SELL |
| REPL | Replimune Group, Inc. | $814M | 26 | SELL |
| SLDB | Solid Biosciences Inc. | $771M | 25 | SELL |
| CBIO | Crescent Biopharma, Inc. | $602M | 26 | SELL |
| NVCT | Nuvectis Pharma, Inc. | $609M | 25 | SELL |
| ANL | Adlai Nortye Ltd. | $805M | 24 | SELL |
| ACRS | Aclaris Therapeutics, Inc. | $730M | 21 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%